Stocks of FibroGen Inc. (NASDAQ:FGEN) traded higher last session on Wall Street, down -6.18% to $0.86.
According to the data, FibroGen Inc. (NASDAQ:FGEN) has 5 analysts covering its stock. The consensus rating among analysts is ‘Underweight’. As we calculate the median target price by taking the range between a high of $2.50 and a low of $2.00, we find $2.25. Given the previous closing price of $0.92, this indicates a potential upside of 144.57 percent. FGEN stock price is now -48.56% away from the 50-day moving average and -93.81% away from the 200-day moving average. The market capitalization of the company currently stands at $90.41M.
A total of 3 analysts have issued a hold rating and 0 have given it a buy rating. Brokers who have rated the stock have averaged $2.25 as their price target over the next twelve months.
With the price target reduced from $4 to $2, BofA Securities Downgraded its rating from Neutral to Underperform for FibroGen Inc. (NASDAQ: FGEN).
In other news, Henderson Jeffrey William, Director sold 2,000 shares of the company’s stock on Sep 01. The stock was sold for $2,060 at an average price of $1.03. Upon completion of the transaction, the Director now directly owns 28,866 shares in the company, valued at $24824.76. An SEC document containing details of the transaction can be found on the SEC’s website. On Aug 04, Director Henderson Jeffrey William sold 2,000 shares of the business’s stock. A total of $3,820 was realized by selling the stock at an average price of $1.91. This leaves the insider owning 30,866 shares of the company worth $26544.76. Insiders disposed of 233,729 shares of company stock worth roughly $0.2 million over the past 1 year. A total of 0.90% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in FGEN stock. A new stake in FibroGen Inc. shares was purchased by AFFINITY ASSET ADVISORS, LLC during the first quarter worth $849,000. SOFINNOVA INVESTMENTS, INC. invested $550,000 in shares of FGEN during the first quarter. In the first quarter, IKARIAN CAPITAL, LLC acquired a new stake in FibroGen Inc. valued at approximately $197,000. GTS SECURITIES LLC acquired a new stake in FGEN for approximately $175,000. POINT72 MIDDLE EAST FZE purchased a new stake in FGEN valued at around $97,000 in the second quarter. In total, there are 245 active investors with 78.70% ownership of the company’s stock.
Friday’s opening bell rang with an opening price of $0.9152 for FibroGen Inc. (NASDAQ: FGEN). During the past 12 months, FibroGen Inc. has had a low of $0.90 and a high of $25.69. The fifty day moving average price for FGEN is $1.6386 and a two-hundred day moving average price translates $13.8861 for the stock.
The latest earnings results from FibroGen Inc. (NASDAQ: FGEN) was released for Jun, 2023. According to the Biotechnology Company, earnings per share came in at -$0.9, missing analysts’ expectations of -$0.7 by -0.2. This compares to -$0.78 EPS in the same period last year. The company reported revenue of $44.32 million for the quarter, compared to $29.81 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 48.69 percent. For the current quarter, analysts expect FGEN to generate $36.84M in revenue.
FibroGen Inc.(FGEN) Company Profile
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, and Duchenne muscular dystrophy; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
